Menu Search
Equities

Sirona Biochem Corp

ZSB:BER

Sirona Biochem Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)0.046
  • Today's Change-0.001 / -2.13%
  • Shares traded8.00k
  • 1 Year change-28.79%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 19:48 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

  • Revenue in CAD (TTM)-12.09k
  • Net income in CAD-2.31m
  • Incorporated2006
  • Employees--
  • Location
    Sirona Biochem Corpc/o WeWork, 595 Burrard St.VANCOUVER V7X 1L4CanadaCAN
  • Phone+1 (604) 641-4466
  • Fax+1 (604) 608-5471
  • Websitehttps://www.sironabiochem.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.